Medicare AdvantagePrior AuthMedium impact
Crotamiton Topical Products (Revised)
Humana·Dermatology, Infectious Disease, General Practice +1 more·Medicare Advantage
Effective date
Jan 1, 2020
We identified it
Jun 25, 2026
Summary
Humana Medicare Advantage updated its prior authorization policy for crotamiton topical products (Crotan, Eurax, Pruradik lotion/cream) effective January 1, 2020, with a revision date of November 26, 2025. The policy requires prior authorization for two distinct indications: (1) scabies treatment only after failure/contraindication/intolerance to both permethrin 5% cream AND oral ivermectin, and (2) pruritic skin treatment only after failure/contraindication/intolerance to both topical corticosteroids AND oral antihistamines. Both initial and renewal approvals are limited to one-year durations.
Action Required
Immediately: Billing and clinical teams must update prior authorization workflows to require documented evidence of previous treatment failure, contraindication, or intolerance to BOTH first-line agents before approving crotamiton topical products for Medicare Advantage members. For scabies claims: require documentation of prior permethrin 5% cream AND oral ivermectin attempts. For pruritic skin claims: require documentation of prior topical corticosteroid (e.g., hydrocortisone, triamcinolone, mometasone) AND oral antihistamine (e.g., hydroxyzine, levocetirizine) attempts. Update encounter forms and EMR templates to include checkboxes for documenting these dual-agent requirements. Configure billing system to automatically generate denial letters if both prior treatments are not documented. Route all crotamiton prior authorization requests to clinical reviewers for manual review with one-year approval duration. Failure to obtain prior authorization or incomplete documentation of dual treatment failures will result in claim denials.